Loading clinical trials...

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women | Clinical Trials | Clareo Health

COMPLETEDNA

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NCT06250283•University of Delaware

Summary

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Detailed Description

We plan to enroll and screen 68 women, with an estimated 34 qualifying women will be randomly assigned to two groups: 1) the placebo group and 2) the resveratrol group. The resveratrol group will receive 500 mg resveratrol daily for 24 weeks, and placebo group will receive placebo pills. Both groups will receive 500 mg calcium plus 400 IU vitamin D daily. Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks.

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1 to 10 years postmenopausal women with low bone mass

Exclusion Criteria

•Osteoporosis
•Taking blood thinners, endocrine, or neuroactive drugs
•Hormone therapy
•Diagnosed: Metabolic bone disease, renal disease, kidney stones, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease
•Severe menopausal symptoms, serious mood alterations, sleep disturbances
•Abnormal uterine bleeding, endometriosis, pelvic inflammatory disease
•Endometrial polyps, and significant uterine fibroids
•Smokers (≥ 20 cigarettes per day)
•BMI \<20 and \> 30 kg/m2
•Intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes, red wine, or blueberries

Locations (1)

University of Delaware

Newark, Delaware, United States

Key Dates

Start Date

February 2, 2024

Primary Completion Date

October 30, 2025

Completion Date

January 30, 2026

Last Updated

March 10, 2026

Enrollment

ACTUAL participants

Conditions

Low Bone Mass

Interventions

Resveratrol

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)

NCT01801397

Low Bone Mass in Anorexia Nervosa Patients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions